PetVivo’s Kush Continues to Demonstrate Effectiveness

Minneapolis, Sept. 23, 2016 --

For Immediate Release:

PetVivo’s Kush Continues to Demonstrate Effectiveness

MINNEAPOLIS, MN September 23, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets continues to see positive results from Kush treatments to both dogs and horses.  

A particularly interesting case is a seven-year-old thoroughbred named Sarge Hudson. Sarge suffered from bone deterioration and cartilage loss in his left ankle (fetlock) joint and it was assumed he would never race again. The horse was given away to a new owner Dustin Williams at no cost. Dustin had both of Sarge Hudson’s fetlocks treated with PetVivo’s Kush particles. The Kush treatments allowed Sarge to return to racing. On August 19 at the Columbus Park track in Columbus, Nebraska Sarge Hudson ran to a first place finish in Race number six. Eight days flowing his win, Sarge went on to a third place finish.

“I am very impressed that the Kush Particles allowed Sarge to return to the track,” noted Dustin William, “It is even more impressive that Sarge returned to the track with a win!”

“We are very optimistic about our Kush product to protect the joint from further damage caused by the lost cartilage and to alleviate the associated pain”, notes Dr. David B. Masters, PetVivo’s Chief Technology Officer. “By replacing the cushion lost by the joint’s damaged cartilage, Kush particles injected into the synovial fluid augment the cartilage effects in the articulating joint space, thus allowing the horse to run without the limiting joint pain.”
PetVivo’s lead product, Kush Canine, a Veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is currently available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.
You can learn more about Kush Canine and PetVivo by visiting the company’s website at www.petvivo.com

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.           
Forward-Looking Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:

John Lai

Chief Executive Officer

PetVivo Holdings, Inc.

Email: [email protected]

Phone: 612-296-7305